Veeva Systems (VEEV)
(Delayed Data from NYSE)
$223.39 USD
+6.94 (3.21%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $242.40 +19.01 (8.51%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$223.39 USD
+6.94 (3.21%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $242.40 +19.01 (8.51%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Zacks News
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
Hologic's (HOLX) New Offering to Revitalize Cynosure Division
by Zacks Equity Research
The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.
Bruker Profits from NANO & CALID, New Buyout Holds Promise
by Zacks Equity Research
Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $92.13, moving +0.1% from the previous trading session.
Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength
by Zacks Equity Research
We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.
Edwards Lifesciences Advances in AI With Bay Labs Tie-Up
by Zacks Equity Research
Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.
CVS Health Aetna Synergy Impressive, PBM Selling Season Solid
by Zacks Equity Research
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
by Zacks Equity Research
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
NuVasive's Monolith Corpectomy System Ok'd for Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
by Zacks Equity Research
Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.
Hill-Rom Adds New Capabilities to Centrella Smart+ Beds
by Zacks Equity Research
Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) see strong testing volumes from new products.
Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff
by Zacks Equity Research
Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.
Myriad Genetics Announces Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.
Illumina (ILMN) Takes Part in NIH Program With Genotype Launch
by Zacks Equity Research
The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.
Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
QIAGEN Partners With Novartis to Expand CDx Tests Suite
by Zacks Equity Research
QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.
Time to Focus on Veeva Systems (VEEV) for Strong Earnings Growth Potential
by Zacks Equity Research
Veeva Systems (VEEV) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Quest Diagnostics Rides on Product Launches, Strategic Deals
by Zacks Equity Research
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
by Zacks Equity Research
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Veeva Systems Announces New DAM Solution for Life Sciences
by Zacks Equity Research
Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed's (CHE) subsidiaries continue to register strong sales.
ResMed to Buy Propeller Health, Widens Respiratory Care Suite
by Zacks Equity Research
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.